Section Arrow
CTNM.NASDAQ
- Contineum Therapeutics
Quotes are at least 15-min delayed:2026/01/08 18:11 EST
After Hours
Last
 9.17
0 (0.00%)
Bid
9.15
Ask
9.16
High 9.17 
Low 8.99 
Volume 77 
Regular Hours (Closed)
Last
 9.17
-0.39 (-4.08%)
Day High 
9.4 
Prev. Close
9.56 
1-M High
13.48 
Volume 
365.03K 
Bid
9.15
Ask
9.16
Day Low
8.6 
Open
9.09 
1-M Low
9.25 
Market Cap 
349.22M 
Currency 美元 
P/E 26.3 
%Yield -- 
10-SMA 11.27 
20-SMA 11.62 
50-SMA 11.27 
52-W High 13.565 
52-W Low 3.35 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.25/-2.23
Enterprise Value
354.03M
Balance Sheet
Book Value Per Share
4.94
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1033-0.0223-17.75%-- 
After Hours 0.1025 -0.0008 -0.77%
ACRVAcrivon Therapeutics1.93-1.02-34.58%-- 
After Hours 1.92 -0.01 -0.52%
VTYXVentyx Biosciences13.84+0.11+0.80%-- 
After Hours 13.79 -0.05 -0.36%
MLTXMoonLake Immunotherapeutics14.34+3.05+27.02%-- 
After Hours 14.55 +0.21 +1.46%
CRMDCorMedix7.51-3.66-32.77%5.05PE
After Hours 7.5509 +0.0409 +0.54%
Industry overview quotes are at least 15 minutes delayed
Business Description
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.